Results 31 to 40 of about 1,805,472 (279)

Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study

PLoS ONE, 2019
Introduction The organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure.
D. Héquet, C. Huchon, A. Soilly, B. Asselain, H. Berseneff, C. Trichot, A. Combes, K. Alves, Thuy Nguyen, R. Rouzier, S. Baffert   +10 more
semanticscholar   +1 more source

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China

Frontiers in Pharmacology, 2022
Background: Tislelizumab, a new high-affinity programmed cell death protein-1 (PD-1) inhibitor, significantly prolonged the overall survival in pretreated non-small-cell lung cancer (NSCLC).
Jinhong Gong, D. Su, Jingjing Shang, Shan Xu, Li-Bo Tang, Zhiqiang Sun, Guangjun Liu   +6 more
semanticscholar   +1 more source

Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis [PDF]

, 2016
PURPOSE: To ascertain resource use, costs and risk of workforce absence in non‐infectious uveitis cases versus matched controls. METHODS: In a retrospective claims analysis of employees in the United States, prevalent (N = 705) and incident (N = 776 ...
Chao, Jingdong, Dick, Andrew D, Joshi, Avani, Macaulay, Dendy, Revol, Cindy, Skup, Martha, Thorne, Jennifer E, Tundia, Namita   +7 more
core   +2 more sources

Lyme borreliosis in Belgium: a cost-of-illness analysis

BMC Public Health, 2022
Background Lyme borreliosis (LB) is the most common tick-borne disease in Europe and North America, yet its economic burden remains largely unknown. This study aimed to estimate the economic cost associated with the different clinical manifestations of ...
Laurence Geebelen, Brecht Devleesschauwer, Tinne Lernout, Katrien Tersago, Yves Parmentier, Herman Van Oyen, Niko Speybroeck, Philippe Beutels   +7 more
doaj   +1 more source

Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands

PLoS ONE, 2023
Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors ...
S. Popping, Lisbeth Versteegh, B. Nichols, D. A. van de Vijver, A. van Sighem, P. Reiss, S. Geerlings, C. Boucher, A. Verbon   +8 more
semanticscholar   +1 more source

The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs [PDF]

, 2011
Background Chronic fatigue syndrome (CFS) is a debilitating chronic illness affecting at least 4 million people in the United States. Understanding its cost improves decisions regarding resource allocation that may be directed towards treatment and cure,
Jin-Mann S Lin, Stephen C Resch, Dana J Brimmer, Andrew Johnson, Stephen Kennedy, Nancy Burstein, Carol J Simon   +6 more
core   +2 more sources

Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore

PLoS ONE, 2017
Diabetic retinopathy (DR) is a leading cause of vision-loss globally among type 2 diabetes (T2DM) patients. Information on the economic burden of DR in Singapore is limited.
Xiao Zhang, Serena Low, Neelam Kumari, Jiexun Wang, K. Ang, Darren Yeo, C. Yip, S. Tavintharan, C. Sum, S. Lim   +9 more
semanticscholar   +1 more source

Cell Proteomic Footprint [PDF]

, 2008
The authentication of mammalian cell cultures and their subpopulations are of tremendous demand in biotechnology and cell therapy. However, current techniques are either not efficient or can be very complex and expensive.
Elena Balashova, Maxim Dashtiev, Petr Lokhov   +2 more
core   +2 more sources

Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples

PLoS ONE, 2016
Objectives To systematically review cost of illness studies for schizophrenia (SC), epilepsy (EP) and type 2 diabetes mellitus (T2DM) and explore the transferability of direct medical cost across countries.
Lan Gao, Hao Hu, F. Zhao, Shuchuen Li
semanticscholar   +1 more source

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study

JHEP Reports, 2020
Background & Aims: Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled with rising prevalence, is a growing public health challenge.
Jamie O'Hara, Alan Finnegan, Harpal Dhillon, Leonardo Ruiz-Casas, Gabriel Pedra, Bethany Franks, George Morgan, Vanessa Hebditch, Bengt Jönsson, Mzwandile Mabhala, Tatjana Reic, Ingo Van Thiel, Vlad Ratziu, Manuel Romero-Gomez, Elisabetta Bugianesi, Jörn M. Schattenberg, Quentin M. Anstee   +16 more
doaj   +1 more source